Boston Scientific denied on patent infringement reversal
This article was originally published in The Gray Sheet
Executive SummaryFirm to appeal a March 27 judgment by a Wilmington, Del. federal court that rejected its motion to overturn a jury verdict that Boston Scientific's Nir stent infringes a Johnson & Johnson patent. Boston Scientific no longer sells the device, which was designed and manufactured by Medinol...
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.